



09-30-02

1641  
#10  
nw

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF: Eisinger et al.

SERIAL NO: 09/653,755

Art Unit: 1641

FILED: September 1, 2001

Examiner: Unassigned

FOR: Recombination Monoclonal Antibody to Phosphotyrosine-Containing Proteins

DOCKET NO: 724650-3

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application. In addition, a supplemental disclosure statement has been filed citing related copending applications.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

X §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits. No fee or statement is required.

\_\_\_\_ §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

\_\_\_\_ The statement as specified in 37 CFR §1.97(e) set out below; OR

RECEIVED

OCT 02 2002

TECH CENTER 1600/2900

\_\_\_\_ The fee of \$ 180.00 under 37 CFR §1.17(p).

\_\_\_\_§1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

(1) a Final Action or under 37 CFR §1.113; OR

(2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND  
is accompanied by:

(1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND

(2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,

(3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).

\_\_\_\_§1.97(e) The undersigned Attorney hereby states that:

\_\_\_\_ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;  
or

\_\_\_\_ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

Serial No: 09/653,755  
Filed: September 1, 2001



EXPRESS MAIL CERTIFICATE

Express Mail Label No. EU556037760US  
Deposit Date: 27 September 2002

I hereby certify that this paper and the attachments hereto are being deposited today with the U.S. Postal Service "Express Mail Post Office To Addressee" service under 37 CFR 1.10 on the date indicated above addressed to:

Commissioner for Patents  
Washington, DC 20231

Alan J. Grant  
Alan J. Grant, Esq.

9/27/02  
Date

Respectfully submitted,

Alan J. Grant

Alan J. Grant, Esq.  
Reg. No. 33,389  
CARELLA, BYRNE, BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN  
6 Becker Farm Road  
Roseland, NJ 07068  
Tel. No.: (973) 994-1700

RECEIVED

OCT 02 2002

TECH CENTER 1600/2900

Form PTO-1449

## INFORMATION DISCLOSURE STATEMENT

Atty. Docket:  
724650-3Serial No.:  
09/653,755

Applicant: Eisinger, et al

Filing Date: September 1, 2001

Group: 1614

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	A1						
	B1						
	C1						
	D1						
	E1						

## FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Sub-Class	Translation
	F1	WO 97 42501 A	13 November 97	WO			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	G1						<input type="checkbox"/> Yes <input type="checkbox"/> No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

H1	Wegener, Anne-Marie Karin, et al, "Distinct domains of the CD3-gamma chain are involved in surface expression and function of the T cell antigen receptor.", Journal of Biological Chemistry, Vol. 270 No. 9, 1995, Pages 4675-4680
I1	Sunanda, R. Narayanan, "Preparative Affinity Chromatography of Proteins", Journal of Chromatography A, Elsevier Science, NL, Vol. 658 No. 2, 14 January 1994 (1994-01-14), Pages 237-258
J1	Kanakura, Y, et al, "Phorbol 12-Myristate 13-Acetate Inhibits Granulocyte-Macrophage Colony Stimulating Factor-Induced Protein Tyrosine Phosphorylation in Human Factor-Dependent Hematopoietic Cell Line", Journal of Biological Chemistry, Vol. 266, No. 1, 1991, Pages 490-495
K1	Jean, Yin Jen Wang, "Antibodies for Phosphotyrosine: Analytical and Preparative Tool for Tyrosyl-Phosphorylated Proteins", Analytical Biochemistry, Vol. 172, 1988, Pages 1-7
L1	Mayer, A, et al, "Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: Preparation of a genetically engineered anti-CEA single chain Fv antibody", European Journal of Cancer, Vol. 34, No. 7, June 1998 (1998-96), Pages 968-976
M1	Trill, John J, et al, "Production of monoclonal antibodies in COS and CHO cells", Current Opinion in Biotechnology, Vol. 6 No. 5, 1995, Pages 553-560

Examiner:

Date Considered:

**EXAMINER:**

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

#155402 v1

RECEIVED

OCT 02 2002

TECH CENTER 1600/2900